Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026)
Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026). // Diabetes & Metabolism. – URL: https://www.sciencedirect.com/science/article/pii/S1262363626000832?dgcid=rss_sd_all
Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026). Diabetes & Metabolism. https://www.sciencedirect.com/science/article/pii/S1262363626000832?dgcid=rss_sd_all
“Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026).” Diabetes & Metabolism.
@article{article3184,
title = {Efficacy and safety of the dual SGLT1 and SGLT2 inhibitor JP-2266 in Type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 2 study (Diabetes Metab J, published online July 29, 2026)},
journal = {Diabetes \& Metabolism},
url = {https://www.sciencedirect.com/science/article/pii/S1262363626000832?dgcid=rss_sd_all}
}